HIFU FDA Approved

Cyclist is back doing what he likes best after HIFU procedure

Matthew Hoffman, 59, was having regular annual physical exams that included blood tests. In 2010 one test showed that the Prostate-­Specific Antigen (PSA) was high. Dr. Michael Lazar advised him to have a biopsy, which was negative. However, precursors for cancer were present, meaning that his situation had to be watched closely. A year later, his PSA level had risen to 7. Another biopsy confirmed that something should to be done. “Dr. Lazar explained various options, including surgery, radiation and High Intensity Focused Ultrasound (HIFU). Most of the alternatives had side effects I didn’t like, so I chose HIFU. Overall, it was a pretty good experience.” As an engineer involved with developing software to test cell phones, Matthew was intrigued by the fact that high intensity sound waves could be used as medical therapy. As this happened before HIFU became FDA approved, [...]

2017-12-13T13:37:19+00:00 August 8th, 2017|

First Prostate Cancer Patient Treated with Minimally Invasive HIFU on West Coast

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center November 18, 2015. San Francisco, CA – HIFU Prostate Services, LLC, a leading provider of minimally- invasive prostate cancer treatment, using High Intensity Focused Ultrasound (HIFU), announced that physician partner and Medical Director, Michael J. Lazar, MD treated the first prostate cancer patient in California with minimally invasive HIFU on November 18, in San Francisco at the San Francisco Surgery Center (SFSC). This will be the second patient ever treated in the country using Sonablate HIFU technology. HIFU Prostate Services has partnered with Lazar and SFSC to establish a HIFU Center of Excellence where patients can receive the recently FDA-cleared Sonablate HIFU treatment. SFSC is located in [...]

2017-12-13T13:37:54+00:00 November 18th, 2015|

Minimally Invasive Prostate Cancer Treatment HIFU Now Available in the U.S.

After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence which are typically reported with surgery and radiation. HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Newly appointed HPS Medical Director Michael J. Lazar, MD is set to provide medical guidance and proctoring to new physicians who will now be trained on the Sonacare® HIFU system in surgery centers around [...]

2017-12-13T13:37:55+00:00 November 12th, 2015|